Literature DB >> 16373327

Atypical uses of atypical antipsychotics.

Nora Selengut Brooke1, Michelle Wiersgalla, Carl Salzman.   

Abstract

Atypical antipsychotic drugs are primarily indicated for the treatment of psychotic disorders such as schizophrenia and schizoaffective disorder. Recently, they have also been used for mood stabilization. This article reviews other, potentially therapeutically useful indications for these medications. In most cases, the evidence supporting these new uses is limited but provocative, and involves only case reports. It has not yet been determined whether the usefulness of atypical antipsychotics for nonpsychotic disorders outweighs their potential to cause serious side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373327     DOI: 10.1080/10673220500433148

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  4 in total

1.  Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats.

Authors:  Tao Sun; Wei He; Gang Hu; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2010-02-16       Impact factor: 3.533

2.  Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide.

Authors:  Alexa Mead; Ming Li; Shitij Kapur
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

3.  Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders.

Authors:  Madhusudan Grover; Spencer D Dorn; Stephan R Weinland; Christine B Dalton; Bradley N Gaynes; Douglas A Drossman
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

4.  Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats.

Authors:  Anna Wesołowska; Joanna Rychtyk; Joanna Gdula-Argasińska; Katarzyna Górecka; Natalia Wilczyńska-Zawal; Magdalena Jastrzębska-Więsek; Anna Partyka
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-25       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.